TOPPER

Tag Archives | Malvern

Reaction Biology Corporation

Paper published: Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

MALVERN, Pa. /CitizenWire/ — Reaction Biology Corporation (‘RBC’) today announced the publication in Nature Biotechnology, of the largest kinase profiling data set in the public domain, disclosing previously unknown kinase inhibition relationships. The data set was compiled from over 100,000 independent activity assays performed with RBC’s proprietary HotSpot(SM) technology.

Continue Reading
Reaction Biology Corporation

Reaction Bio announces new product line, recombinant proteins for epigenetic research

MALVERN, Pa. /CitizenWire/ — Reaction Biology Corporation (‘RBC’), a leading contract research organization providing drug discovery services in epigenetics, today announced the rollout of a new product line, recombinant proteins for epigenetic research. RBC’s initial offerings will emphasize the histone methyltransferases (HMTs), including exclusive targets for which there has been no previous commercial source.

Continue Reading
drug discovery

National Cancer Institute Grant for Epigenetic Platform Awarded to Reaction Biology Corp.

MALVERN, Pa. — Reaction Biology Corporation (RBC) announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpot drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC’s methyltransferase screens from 14 to 35 or more.

Continue Reading

Part of the Neotrope® News Network, USA.